VI PHAN: Open Payments
NPI 1386287514 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,493 in 58 payments from 14 companies in 2025. Trend: 2023 $636 · 2024 $1,707 · 2025 $1,493
Food & beverage: $1,493
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 6 | $443 |
| Novartis Pharmaceuticals Corporation | 8 | $219 |
| BridgeBio Pharma, Inc. | 8 | $159 |
| AstraZeneca Pharmaceuticals LP | 8 | $142 |
| Amgen Inc. | 9 | $135 |
| Esperion Therapeutics, Inc. | 6 | $96 |
| Novo Nordisk Inc | 3 | $71 |
| Alnylam Pharmaceuticals Inc. | 2 | $60 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| SCPHARMACEUTICALS INC. | 2 | $35 |
Products named: CARDIOMEMS, LEQVIO, Attruby, FARXIGA, REPATHA, NEXLETOL, Wegovy, AMVUTTRA.
Industry payments across TX — which companies pay providers there.
